Rifampin
Rifadin, Rifamate, Rifampin, Rifater, Rimactane (rifampin) is a small molecule pharmaceutical. Rifampin was first approved as Rifamate on 1982-01-01. It is used to treat aids-related opportunistic infections, bacterial infections, bacterial meningitis, brucellosis, and haemophilus infections amongst others in the USA. It is known to target solute carrier organic anion transporter family member 1A2, solute carrier organic anion transporter family member 1B1, solute carrier organic anion transporter family member 1B3, and nuclear receptor subfamily 1 group I member 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Rifadin, Rifampin, Rimactane (discontinued: Rifadin, Rifampin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rifampin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RIMACTANE | Oxford Pharmaceuticals | N-050429 RX | 1982-01-01 | 1 products |
| RIFADIN | Sanofi | N-050627 RX | 1989-05-25 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mycobutin | New Drug Application | 2024-12-24 |
| priftin | New Drug Application | 2025-05-21 |
| rifabutin | NDA authorized generic | 2025-09-30 |
| rifadin | 2007-07-16 | |
| rifadin iv | New Drug Application | 2025-05-14 |
| rifadin iv novaplus | New Drug Application | 2025-05-14 |
| rifadin rifadin iv | New Drug Application | 2021-12-01 |
| rifadin rifadin iv novaplus | New Drug Application | 2017-05-04 |
| rifampin | ANDA | 2025-09-19 |
| talicia | New Drug Application | 2024-05-01 |
Show 1 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J04: Antimycobacterials
— J04A: Drugs for treatment of tuberculosis
— J04AB: Antibiotics, antitubercular
— J04AB02: Rifampicin
— J04AM: Combinations of drugs for treatment of tuberculosis
— J04AM02: Rifampicin and isoniazid
— J04AM05: Rifampicin, pyrazinamide and isoniazid
— J04AM06: Rifampicin, pyrazinamide, ethambutol and isoniazid
— J04AM07: Rifampicin, ethambutol and isoniazid
— J04B: Drugs for treatment of lepra
— J04BA: Drugs for treatment of lepra
— J04BA50: Dapsone and rifampicin
— J04BA51: Dapsone, rifampicin and clofazimine
HCPCS
No data
Clinical
Clinical Trials
702 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 35 | 81 | 50 | 29 | 62 | 239 |
| Healthy volunteers/patients | — | — | — | 118 | 1 | 1 | 1 | 5 | 125 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 6 | 52 | 30 | 6 | 17 | 100 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 9 | 21 | 16 | 12 | 12 | 64 |
| Infections | D007239 | EFO_0000544 | — | 3 | 6 | 10 | 4 | 12 | 34 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | — | 7 | 9 | 2 | 11 | 27 |
| Communicable diseases | D003141 | — | — | — | 3 | 6 | 3 | 10 | 22 |
| Drug interactions | D004347 | — | — | 18 | 1 | — | 3 | 1 | 22 |
| Latent tuberculosis | D055985 | — | Z22.7 | 3 | 4 | 8 | 4 | 6 | 22 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 2 | 4 | 6 | 4 | 7 | 21 |
Show 48 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Meningeal tuberculosis | D014390 | — | A17.0 | 1 | 9 | 3 | — | 1 | 12 |
| Coinfection | D060085 | — | — | — | 3 | 2 | — | 2 | 7 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | 3 | — | 1 | 5 |
| Aids-related opportunistic infections | D017088 | — | — | — | — | 1 | — | 4 | 5 |
| Meningitis | D008581 | EFO_0000584 | G03 | — | 2 | 1 | — | 1 | 4 |
| Buruli ulcer | D054312 | EFO_1001281 | A31.1 | — | 3 | 2 | — | 1 | 4 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | 2 | 1 | — | — | 3 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | 1 | — | 1 | — | 1 | 3 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | 1 | 1 | — | 1 | 3 |
| Immunologic deficiency syndromes | D007153 | — | D84.9 | — | — | 2 | — | 1 | 3 |
Show 34 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 33 | 1 | — | — | — | 34 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 7 | 7 | — | — | — | 11 |
| Lymphoma | D008223 | — | C85.9 | 8 | 1 | — | — | — | 9 |
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | 5 | — | — | — | 7 |
| Melanoma | D008545 | — | — | 4 | 3 | — | — | — | 6 |
| Pharmacokinetics | D010599 | — | — | 4 | 1 | — | — | — | 5 |
| Recurrence | D012008 | — | — | 4 | 2 | — | — | — | 5 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | 2 | 2 | — | — | 1 | 4 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 3 | 1 | — | — | — | 4 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | 3 | — | — | — | 4 |
Show 68 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 8 | — | — | — | — | 8 |
| Non-small-cell lung carcinoma | D002289 | — | — | 6 | — | — | — | — | 6 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 3 | — | — | — | — | 3 |
| Primary myelofibrosis | D055728 | — | D47.4 | 2 | — | — | — | — | 2 |
| Biological availability | D001682 | — | — | 2 | — | — | — | — | 2 |
| Thrombosis | D013927 | — | — | 2 | — | — | — | — | 2 |
| Bacterial infections | D001424 | — | A49 | 1 | — | — | — | 1 | 2 |
| Respiratory syncytial virus infections | D018357 | EFO_1001413 | — | 2 | — | — | — | — | 2 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | — | — | — | — | 2 |
| Rhinoscleroma | D012226 | EFO_0007470 | — | 2 | — | — | — | — | 2 |
Show 43 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Critical illness | D016638 | — | — | — | — | — | — | 2 | 2 |
| Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 2 | 2 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 2 | 2 |
| Bone diseases | D001847 | — | M89.9 | — | — | — | — | 1 | 1 |
| Infectious bone diseases | D001850 | — | — | — | — | — | — | 1 | 1 |
| Acinetobacter infections | D000151 | EFO_1000792 | — | — | — | — | — | 1 | 1 |
| Scrub typhus | D012612 | EFO_0007480 | A75.3 | — | — | — | — | 1 | 1 |
| Epidemic louse-borne typhus | D014438 | EFO_0007182 | A75 | — | — | — | — | 1 | 1 |
| Birth weight | D001724 | EFO_0004344 | — | — | — | — | — | 1 | 1 |
| Granuloma | D006099 | — | — | — | — | — | — | 1 | 1 |
Show 19 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rifampin |
| INN | rifampicin |
| Description | Rifampicin, also known as rifampin, is an ansamycin antibiotic used to treat several types of bacterial infections, including tuberculosis (TB), Mycobacterium avium complex, leprosy, and Legionnaires' disease. It is almost always used together with other antibiotics with two notable exceptions: when given as a "preferred treatment that is strongly recommended" for latent TB infection; and when used as post-exposure prophylaxis to prevent Haemophilus influenzae type b and meningococcal disease in people who have been exposed to those bacteria. Before treating a person for a long period of time, measurements of liver enzymes and blood counts are recommended. Rifampicin may be given either by mouth or intravenously.
|
| Classification | Small molecule |
| Drug class | tricyclic compounds; antibiotics (rifamycin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C |
Identifiers
| PDB | — |
| CAS-ID | 13292-46-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL374478 |
| ChEBI ID | 28077 |
| PubChem CID | 5381226 |
| DrugBank | DB01045 |
| UNII ID | VJT6J7R4TR (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLCO1A2
SLCO1A2
SLCO1B1
SLCO1B1
SLCO1B3
SLCO1B3
NR1I2
NR1I2
Organism
Homo sapiens
Gene name
SLCO1A2
Gene synonyms
OATP, OATP1, OATP1A2, SLC21A3
NCBI Gene ID
Protein name
solute carrier organic anion transporter family member 1A2
Protein synonyms
OATP-1, OATP-A, organic anion transporting polypeptide A, Organic anion-transporting polypeptide 1, Sodium-independent organic anion transporter, solute carrier family 21 (organic anion transporter), member 3, Solute carrier family 21 member 3
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Rifampin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 48,414 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
36,446 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use